Clinical trials: Docetaxel
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Hormone Refractory Prostate Cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of…
- Trial name
- NCT00571675
- Testing
- AT-101, prednisone and docetaxel
- Where
- 35 sites in United States, Russia
- Volunteers
- 220 people
- Sponsor
- Ascenta Therapeutics
Non-small Cell Lung Cancer, Lung Cancer
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC).
- Trial name
- ZODIAC (NCT00312377)
- Testing
- Docetaxel, Vandetanib
- Where
- 156 sites in United States, Argentina and 23 more
- Volunteers
- 1,690 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer, Prostate
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
The goal of this study is to evaluate the efficacy and safety of darolutamide combined with docetaxel and ADT compared to docetaxel combined with ADT in treating locally advanced prostate cancer patients scheduled for radical…
- Conditions
- Prostate Cancer, Prostate, Prostate Cancer Patients
- Trial name
- NCT07730151
- Testing
- Darolutamide, docetaxel, ADT
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Gastric Cancer, Esophageal Neoplasms
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after receiving treatment with the drugs irinotecan (also known as CPT-11) and…
- Trial name
- NCT00183872
- Testing
- irinotecan, docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
NSCLC
Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer
- Trial name
- NCT02179567
- Testing
- Docetaxel, Bevacizumab
- Where
- 5 sites in Greece
- Volunteers
- 26 people
- Sponsor
- Hellenic Oncology Research Group
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04721015
- Testing
- ABBV-637, Docetaxel, Osimertinib
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Adult Solid Neoplasm, Inflammatory Breast Carcinoma
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Phase I/II trial to study the effectiveness of neoadjuvant tipifarnib combined with docetaxel and capecitabine in treating patients who have locally advanced or metastatic solid tumors or stage IIIA or stage IIIB breast cancer.
- Conditions
- Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma, Stage IIIA Breast Cancer
- Trial name
- NCT00070252
- Testing
- Capecitabine, Docetaxel, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- S0217 (NCT00084435)
- Testing
- cisplatin, docetaxel, radiation therapy
- Where
- 29 sites in United States
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
This phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.
- Trial name
- SOBER (NCT03367676)
- Testing
- Trastuzumab, Docetaxel
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of…
- Trial name
- NCT06525350
- Testing
- Glumetinib tablets, HB1801 (docetaxel, albumin-bound）, Docetaxel
- Volunteers
- 256 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- oligo-mets (NCT02716974)
- Testing
- Leuprolide Acetate, Bicalutamide, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma
ARQ 501 in Combination With Docetaxel in Patients With Cancer
The purpose of this study is to determine the safety of ARQ 501 in combination with docetaxel in patients with advanced or metastatic cancer.
- Trial name
- NCT00099190
- Testing
- ARQ 501
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer(NSCLC)
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
To compare clinical response (complete response and partial response) by RECIST) rates by RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy
- Trial name
- Oncology (NCT02036359)
- Testing
- erlotinib, docetaxel
- Where
- Taiwan
- Volunteers
- 76 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Neoplasms
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
- Trial name
- NCT00617968
- Testing
- DOCETAXEL
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
- Trial name
- DUBLIN-3 (NCT02504489)
- Testing
- Docetaxel + Plinabulin (DP), Docetaxel (D)
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 559 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Non Squamous Non Small Cell Lung
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination…
- Trial name
- NCT02766140
- Testing
- SHR1020 plus Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.